Navigation Links
Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:7/26/2010

LAKE FOREST, Ill., July 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

The controlled, randomized trial of patients on hemodialysis who have already been treated with Amgen's Epogen® (epoetin alfa), is taking place at 20 different hemodialysis centers across the United States. Patients in the trial will be treated with both Epogen and Hospira's EPO, with each patient receiving one drug first and then being switched to the second drug. The goal of the Phase I trial is to test safety and pharmacokinetics, or measurements of the drug's blood level and distribution in the body, compared with the reference product. Pending successful completion of the Phase I trial, Hospira would launch an expanded Phase III trial in 2011, also comparing safety and efficacy of Hospira's EPO with Epogen.

"This trial marks a key milestone for Hospira's biosimilars program," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "Congressional approval of a regulatory pathway for biosimilar drugs in the U.S. set the stage for our development of a U.S. biosimilar EPO. We hope to leverage our leadership in generics and our biosimilars experience in '/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
2. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
3. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
4. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
7. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
8. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
9. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
10. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , MONDAY, Jan. 10 (HealthDay News) -- The ... how to create a vaccine that can protect people against ... that people who were infected with the H1N1 virus and ... against a wide variety of flu strains. The virus ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... path through Rep. Gabrielle Giffords, brain on Saturday will likely ... point how extensive that damage might be. However, doctors ... Arizona congresswoman immediately after the shooting are already encouraged by ...
... is a highly subjective experience. We each have a pain ... A paper in the International Journal of Behavioural and ... pain in research. There are many chronic illnesses and ... because of the subjectivity in a patient,s reporting of their ...
... type of skin cancer. In this paper, Leif Ellisen and ... and p73 in SCC cells, and discovered a feedback loop ... SCC, they found that inhibiting one of these miRs decreased ... highlighting a new potential therapeutic target. , Squamous cell carcinoma ...
... researchers have found that a protein that plays an important ... due to additional mechanisms that cause it to promote atherosclerosis, ... the January issue of the journal Arteriosclerosis, Thrombosis and ... why some antioxidant therapies have not yielded more positive results. ...
... change during the 20th century in England and Wales in ... features in Alcohol and Alcoholism . While deaths ... the early part of the century, the pattern changed so ... lower social classes by the end of the century. ...
Cached Medicine News:Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 3Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 4Health News:Does it hurt? 2Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2Health News:Social class and changes in mortality from liver cirrhosis over the 20th Century 2
Provides exceptional resolution and fundus scanning capability. Excellent for small pupil diagnosis and treatment....
... 20D diagnostic/laser lens is perfectly corrected ... coma delivering the best retinal ... on the market. Its advanced double ... magnification and perfect image clarity across ...
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... The NIDEK MK-2000 ... performance in a wide ... MK-2000 utilizes single-use, ultra-sharp ... Blades are supplied sterile ...
Medicine Products: